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Abstract
Cancer is one of the leading cause of death, worldwide. Many believe that
genomic data will enable us to better predict the survival time of these
patients, which will lead to better, more personalized treatment options
and patient care. As standard survival prediction models have a hard time
coping with the high-dimensionality of such gene expression data, many
projects use some dimensionality reduction techniques to overcome this
hurdle. We introduce a novel methodology, inspired by topic modeling
from the natural language domain, to derive expressive features from the
high-dimensional gene expression data. There, a document is represented
as a mixture over a relatively small number of topics, where each topic
corresponds to a distribution over the words; here, to accommodate the
heterogeneity of a patient’s cancer, we represent each patient
(≈ document) as a mixture over cancer-topics, where each cancer-topic is a
mixture over gene expression values (≈ words). This required some
extensions to the standard LDA model – e.g., to accommodate the
real-valued expression values – leading to our novel discretized Latent
Dirichlet Allocation (dLDA) procedure. After using this dLDA to learn
these cancer-topics, we can then express each patient as a distribution over
a small number of cancer-topics, then use this low-dimensional
“distribution vector” as input to a learning algorithm – here, we ran the
recent survival prediction algorithm, MTLR, on this representation of the
cancer dataset. We initially focus on the METABRIC dataset, which
describes each of n=1,981 breast cancer patients using the r=49,576 gene
expression values, from microarrays. Our results show that our approach
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(dLDA followed by MTLR) provides survival estimates that are more
accurate than standard models, in terms of the standard Concordance
measure. We then validate this “dLDA+MTLR” approach by running it
on the n=883 Pan-kidney (KIPAN) dataset, over r=15,529 gene expression
values – here using the mRNAseq modality – and find that it again
achieves excellent results. In both cases, we also show that the resulting
model is calibrated, using the recent “D-calibrated” measure. These
successes, in two different cancer types and expression modalities,
demonstrates the generality, and the effectiveness, of this approach.
1 Introduction
The World Health Organization reports that cancer has become the second
leading cause of death globally, as approximately 1 in 6 deaths are caused
by some form of cancer [1]. Moreover, cancers are very heterogeneous, in
that the outcomes can vary widely for patients with similar diagnoses, who
receive the same treatment regimen. This has motivated researchers to
seek other features to help predict individual outcomes. Many such
analyses use just clinical features. Unfortunately, features such as lymph
node status and histological grade, while predictive of metastases, do not
appear to be sufficient to reliably categorize clinical outcome [2]. This has
led to many efforts to improve the prognosis for cancer, based on genomics
data (e.g., gene expression (GE) or copy number variation (CNV) ),
possibly along with the clinical data [2–6]. Focusing for now on breast
cancer, van’t Veer et al. [2] used the expression of 70 genes to distinguish
high vs low risk of distant metastases within five years. Parker et al. [4]
identified five subtypes of breast cancer, based on a panel of 50 genes
(PAM50): luminal A, luminal B, HER2-enriched, basal-like, and
normal-like. Later, Curtis et al. [7] examined ≈2000 patients from a wide
study combining clinical and genomic data, and identified around ten
subtypes. All three of these studies showed that their respective subtypes
produce significantly different Kaplan-Meier survival curves [8], suggesting
such molecular variation does influence the disease progression.1
More recently, many survival prediction models have been applied to
cancer cohorts, with the goal of estimating survival times for individual
patients; some are based on standard statistical survival analysis
techniques, and others based on classic regression algorithms – e.g.,
random survival forests [9] or support vector regression for censored data
(SVRc) [10]. With the growing number of gene expression experiments
being cataloged for analysis, we need to develop survival prediction models
1 There are also many other systems that use such expression information to divide
the patients into two categories: high- vs low-risk; cf., [2, 6].
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that can utilize such high dimensional data. Our work describes such a
system that can learn effective survival prediction models from
high-dimensional gene expression data.
The 2012 DREAM Breast Cancer Challenge (BCC) was designed to
focus the community’s efforts to improve breast cancer survival
prediction [3]. Its organizers made available clinical and genomic data (GE
and CNV) of ≈2000 patients from the [7] study (mentioned above). Each
submission to the BCC challenge mapped each patient to a single real
value (called “risk”), which is predicting that patients with higher risk
should die earlier than those with lower risk. The entries were therefore
evaluated based on the concordance measure: basically, the percentage of
these pairwise predictions that were correct [11]. This is standard, in that
many survival prediction tasks use the concordance as the primary
measure to assess the performance of the survival predictors, here and in
other challenges [12]. The winning model [13] performed statistically
better than the state-of-the-art benchmark models [3].
This paper explores several dimensionality reduction technique,
including a novel approach based on topic modeling, “discretized Latent
Dirichlet Allocation” (dLDA), seeking one that can produce highly
predictive features from the high-dimensional gene expression data. We
explored several ways to apply this topic-modeling approach to gene
expression data, to identify the best ways to use it to map the gene
expression description into a much lower dimensional description (from
≈50K features to 30 in this METABRIC dataset). We then gave the
resulting transformed data as input to a recently-developed non-parametric
learning algorithm, multi-task logistic regression (MTLR), which produced
a model that can then predict an individual’s survival distribution [14]. We
show that this predictor performs better than other standard survival
analysis tools in terms of concordance. We also found that it was
“D-calibrated” [15,16]; see Appendix B.2.
To test the generality of our learning approach (dLDA + MTLR), we
then applied the same learning algorithm – the one that worked for the
METABRIC microarray gene expression dataset – to the Pan-Kidney
dataset, which is a different type of cancer (kidney, not breast), and is
described using a different type of features (mRNAseq, not microarray).
We found that the resulting predictor was also extremely effective, in terms
of both concordance and D-calibration.
This paper provides the following three contributions: (1) We produce
an extension to LDA, called “dLDA”, needed to handle continuous data;
(2) we use this as input to a survival prediction tool, MTLR – introducing
that tool to this bioinformatics community; and (3) we demonstrate that
this dLDA+MTLR combination works robustly, in two different datasets,
using two different modalities – working better than some other standard
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approaches, in survival prediction.
Section 2 introduces the basic concepts, related to the survival
prediction task in general and latent dirichlet allocation; Section 3 then
describes the datasets used in this study; and Section 4 presents an
overview of learning and performance tasks, at a high level. Section 5
(resp., 6, 7) then presents our results (resp., discussions, contributions).
The supplementary appendices provide additional figures, tables, and other
and material – e.g., defining some of the terms, and introducing
“D-calibration”.
2 Foundations
This section provides the foundations: Section 2.1 overviews the survival
prediction task in general then Section 2.2 describes Latent Dirichlet
Allocation (LDA), first showing its original natural language context, then
discussing how we need to extend it for our gene expression context. These
significant modifications lead to a discretized variant, dLDA. We also
contrast this approach with other survival analysis of gene expressions.
2.1 Survival prediction
Survival prediction is similar to regression as both involve learning a model
that regresses the covariates of an individual to estimate the value of a
dependent real-valued response variable – here, that variable is “time to
event” (where the standard event is “death”). But survival prediction
differs from the standard regression task as its response variable is not
fully observed in all training instances – this tasks allows many of the
instances to be “right censored”, in that we only see a lower bound of the
response value. This might happen if a subject was alive when the study
ended, meaning we only know that she lived at least (say) 5 years after the
starting time, but do not know whether she actually lived 5 years and a
day, or 30 years. This also happens if a subject drops out of a study, after
say 2.3 years, and is then lost to follow-up; etc. Moreover, one cannot
simply ignore such instances as it is common for many (or often, most) of
the training instances to be right-censored; see Table 1. Such “partial label
information” is problematic for standard regression techniques, which
assume the label is completely specified for each training instance.
Fortunately, there are survival prediction algorithms that can learn an
effective model, from a cohort that includes such censored data. Each such
dataset contains descriptions of a set of instances (e.g., patients), as well as
two “labels” for each: one is the time, corresponding to the time from
diagnosis to a final date (either death, or time of last follow-up) and the
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Fig 1. Survival prediction training and performance tasks. Training-Task:
Historical data with event times and censor-status along with covariates
are used to train a model – top-to-bottom. Performance-Task: new patient
covariates are input to the learned model to produce a prediction of
survival time – bottom, left-to-right. (Included picture designed by
Freepik.)
other is the status bit, which indicates whether the patient was alive at
that final date (Figure 1).
2.1.1 Patient Specific Survival Prediction using the MTLR
Model
This project considered 3 ways to learn a survival model: The standard
approaches – Cox and Regularized Cox (RCox) – are overviewed in
Appendix A.5. This subsection describes the relatively-new MTLR [14]
system, which learns a model (from survival data) that, given a description
of a patient x ∈ <r, produces a survival curve, which specifies the
probability of death D, P( D ≥ t | x ) vs t for all times t ≥ 0. This
survival curve is similar to a Kaplan–Meier curve [8], but incorporates all
of the patient specific features x. In more detail: MTLR first identifies m
time points {ti}i=1..m and then learns a variant of a logistic regression
function, parameterized by W = {[wi, bi]}i=1..m over these m time points, a
different such function for each time ti – meaning W is a matrix of size
m× (r + 1). Using the random variable D for the time of death for the
patient described by x:
PrW (D ∈ [tk, tk+1) | x ) ∝ exp
(
m∑
`=k+1
(w`
Tx + b`)
)
(1)
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The MTLR model then combines the values of the PMF (probability mass
function) into a CMF (cumulative mass function), by adding them in the
reverse order – hence from the probability value of 1 at t0 = 0 – i.e.,
PrW (D ≥ 0 | x ) = 1 – down to smaller values as the time t increases.
Figure 2 shows the individual survival curves of several patients. Here, we
view a patient’s descretized survival time d ∈ <≥0 as a binary vector (of
classification labels) y(d) = [y1(d), y2(d), . . . , ym(d)], where each
yj(d) ∈ {0, 1} encodes that patient’s survival status at each time interval
[tj, tj+1]: yj(d) = 0 (no death yet) for all j with tj < d and yj(d) = 1
(death) for all tj ≥ d. The learning system attempts to optimize
min
W
C
2
m∑
j=1
‖wj‖2 −
n∑
i=1
 m∑
j=1
yj(di)(w
Txi + bj)− log
m∑
k=0
exp(fW (xi, k))

where fW (xi, k) =
m∑
`=(k+1)
(wT` xi + b`) for 0 ≤ k ≤ m
(2)
(This formula applies to uncensored patients; we apply the obvious
extension to deal with censored instances.) This overall equation includes a
L2 regularization term to reduce the risk of overfitting. The MTLR
parameter m (the number of time points) is set to the square-root of the
number of instances in all our experiments.
Given the learned parameters W , we can then use Equation 1 to
produce a curve for each patient; we can then use the (negative of) the
mean of the patient’s specific predicted survival distribution as her risk
score. Yu et al. [14] presents more detailed explanations of model
formulation, parameter learning (W ), and the prediction task. MTLR
differs from many other models (such as the standard Cox model) as:
(1) MTLR produces a survival function, rather than just a risk score; and
(2) MTLR does not make the proportional hazards assumption – i.e., it
allows effect of each covariate to change with time. See also
Haider et al. [16]. Note this is the learning process of LearnSurvivalModel
(LSM[Ψ = MTLR]) appearing below in Figure 3, and Section 4.1.
2.2 Discretized Latent Dirichlet Allocation (dLDA)
Latent Dirichlet Allocation (LDA) is a widely used generative model [17],
with many successful applications in natural language (NL) processing.
LDA views each document as a distribution over multiple topics
(document-topics distribution), where each topic is a distribution over a set
of words (topic-words distribution) – that is, LDA assumes that each word
in a document is generated by first sampling a topic from the document’s
October 28, 2019 6/41
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Fig 2. The dashed line is the Kaplan-Meier plot for this dataset. Each of
the other 5 curves is a patient-specific survival curve, for 5 different
METABRIC patients, from a learned MTLR model. The curves show that
there are very different prognoses for the different patients, even though
they all are breast cancer patients from the same cohort: here, the patient
with the orange survival curve (near the top) has a very good prognosis,
especially compared to the patient with the blue survival curve.
document-topics distribution and then sampling a word from the selected
topic’s topic-words distribution. Given the set of topics (each
corresponding to a specific topic-word distribution), we can view each
document as its distribution over topics, which is very low dimensional.
The LDA learning process first identifies the latent topics – that is, the
topic-words distributions corresponding to each latent topic – based on the
words that frequently co-occur across multiple documents; n.b., it just uses
the documents themselves, but not the labels. For example, it might find
that many documents with the word “ball” also included “opponent” and
“score”; and vice versa. Similarly, “finances”, “transaction”, and “bank”
often co-occur, as do “saint”, “belief” and “pray”. Speaking loosely, the
topic-model-learner might then form one topic, β¯1, that gives high
probabilities to the first set of words (and relatively low probabilities to
the remaining words) – perhaps 2
P( ball | β¯1 ) = 0.05
P( opponent | β¯1 ) = 0.03
P( score | β¯1 ) = 0.01
P( x | β¯1 ) < 1E-4 for all other words x
This β¯1 corresponds to an n-tuple over the n words; we call this
β¯1 ≈ [P( w1 | β¯1 ), . . . , P( wn | β¯1 )]. It would similarly identify a second
topic β¯2 with the n-tuple β¯2 ≈ [P( w1 | β¯2 ), . . . , P( wn | β¯2 )] that gives
2 Technically, each topic is specified as a Dirichlet distribution over the set of words,
βi. To simplify the presentation, here we are showing their expected values, these
β¯i = E[βi] values are based on the priors; see Appendix A.2(3).
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high probabilities to the different set of words, etc. (While we might view
the first topic as related to sports, the second related to finances, and third
to religion, that is simply our interpretation, and is not needed by the
learning algorithm. Other topics might not be so obvious to interpret.)
This produces the topic-words distribution B = {β¯i}i=1..K over K topics.
The learner would then map each document into a “distribution” over
this set of K topics – perhaps document f1 would be decomposed as
Θ( f1 ) = [θ1( f1 ), θ2( f1 ), . . . , θK( f1 )] = [0.01, 13.02, 50.01 . . . , 0.03] –
these are parameters for a Dirichlet distribution, which are non-negative,
but do not add up to 1. These are different for different documents – e.g.,
perhaps f2 is expressed as Θ( f2 ) = [12.03, 0.001, 3.1, . . . , 2.4], etc. This
is the document-topic distribution {Θ( fj ) }j=1..m over the m documents.
The specific learning process depends on the distributional form of the
document-topics and topic-words distributions (here, we use Dirichlet for
both) and also the number of latent topics, K. Given this, the LDA
learning process finds the inherent structure present in the data – i.e., a
model (topic-words distributions for each of the K topics {β¯i}i=1..K) that
maximizes the likelihood of the training data.
The same way certain sets of words often co-occur in a document,
similarly sets of genes are known to be co-regulated: under some condition
(corresponding to a “c topic”), every gene in that set will have some
additional regulation – some will be over-expressed, each by its own
amount, and the others will be under-expressed. Moreover, just as a
natural language (NL) topic typically involves relatively few words, most
c topics effectively involve relatively few genes. Also, just like a document
may involve a mixture of many topics, each to its own degree, so a patient’s
cancer often involves multiple c topics; see work on cancer subclones [18].
This has motivated many researchers to use some version of topic modeling
to model gene expression values, under various (sets of) conditions.
For example, Rogers et al. [19] proposed
Latent Process Decomposition (LPD), a probabilistic graphical model
that was inspired by LDA, for microarray data, and presented clustering of
genes that led to results comparable to those produced by hierarchical
clustering. (Their results are descriptive; they do not use the results in any
downstream evaluation.) Later Masada et al. [20] proposed improvements
to the original LPD approach and showed similar results. Bicego et al. [21]
report topic modeling approaches (including LPD) were useful in
classification tasks with gene expression data. They applied several topic
models as dimensionality reduction tools to 10 different gene expression
data sets, and found that the features from the topic models led to better
predictors.
Further, Lin et al. [22] reviewed various different topic models applied
to gene expression data, including LDA and probabilistic latent semantic
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analysis (PLSA) [23], as well as the topic model approaches described
above, for gene classification and clustering. They note that the topic
model approaches improve over other models as one can easily interpret
the topic-words distributions and the mixed membership nature of the
document-topic distribution.
However, none of these tasks were survival analysis. They used shifting
and scaling to convert the continuous gene expression values to discrete
values; we considered this approach for our data, but found that it was not
able to learn distinct topics for our data. Moreover, this gave all patients
very similar document-topic distributions. Dawson et al. [24] proposed a
survival supervised LDA model, called survLDA, as an extension of
supervised LDA [25]. survLDA uses a Cox model [26] to model the
response variable (survival time) instead of the generalized linear
model [27] used in supervised LDA [25]. But Dawson et al. [24] reported
that the topics learned from survLDA were very similar to the ones learned
from the general (unsupervised) LDA model.
Here, we apply the “standard” topic-modeling approach to gene
expression data, for the survival prediction task. While previous systems
applied topic modeling techniques to gene expression data, very few have
applied topic models to predict a patient’s survival times (and none to our
knowledge have used mRNAseq expression data). Our work presents a
more direct analogue to the NL topic modeling that can be applied to our
cohort of patients with gene expression data, where each patient
corresponds to a document and the genes/probes in the expression data
correspond to the words that form the document. This requires making
some significant modifications to the standard LDA model, which assumes
the observations are frequencies of words, which are non-negative integers
that generally follows a monotonically decreasing distribution. By contrast,
gene expression values are arbitrary real values, believed to follow a skewed
Gaussian distribution [28]; see also Figure 4. (This is also true for
mRNAseq, as we need to normalize the expression counts to be
comparable, from patient to patient.)
We follow the approach of explicitly discretizing the expression values in
a preprocessing step, so the resulting values basically, approximate a Zipf
distribution. There are still some subtleties here – e.g., while the NL
situation involves only non-negative integers, an affected gene can be either
over-expressed, or under-expressed – i.e., we need to deal with two
directions of “deviation”, while NL’s LDA just deals with one direction;
see Section 4.1.1. We refer to our model as dLDA and the discretized gene
expression values as dGEVs. The same way the standard LDA approach
reduces the description of a document from a ≈ 105-dimensional vector
(corresponding to the words used in that document) to a few dozen values
(the “distribution” of the topics), this dLDA approach reduces the
October 28, 2019 9/41
Table 1. Characteristics of METABRIC and KIPAN Cohorts
METABRIC KIPAN
# Patientsa 1,981 883
# Censored 1,358 (∼ 68.5%) 655 (∼ 74.4%)
# Uncensored 623 228
Time span in days (Uncensored) 3 – 8,941 2 – 5,925
# Clinical features 19 10
# Expressions (≈ #genes)b 49,576 (probes) 15,529
Gender Women (100%) Women (32.7%), Men (67.3%)
a We removed the ∼50 patients from the KIPAN dataset that did not contain
mRNAseq data.
b While METABRIC also included copy number variations (CNV) data for the
patients, here we focus on only gene expression data.
≈ 50K-dimensional gene expression tuple to a few dozen values – here the
“distribution” of the c topics. Figure 5 summarizes this process: using the
subroutines defined in Section 4 below, at learning time,
ComputeBasis[ρ =dLDA] first identifies the set of relevant c topics β¯GE
from the set of gene expression values X ′GE, then later (at performance
time), UseBasis[ρ =dLDA] uses those learned c topics to transform a new
patient’s high-dimensional gene expression profile x′GE to a
low-dimensional c topic-profile, x”GE – here going from 50K values to 30.
Section 5 presents empirical evidence that this method works effectively
for our survival prediction task; Appendix C.1 shows that it performs
better than the LPD technique.
3 Datasets Used
We apply our methods to two large gene expression datasets: the
METABRIC breast cancer cohort [7] (mircroarray) and the Pan-kidney
cohort KIPAN (mRNAseq) [29] 3. We initially focus on the METABRIC
dataset 4, which is one of the largest available survival studies that
includes genomic information. In 2012, the Breast Cancer Prognostic
Challenge (BCC) organizers released the METABRIC (Molecular
Taxonomy of Breast Cancer International Consortium) dataset for
training [7]. While they subsequently released a second dataset (OSLO) for
final testing [7], we are not using it for several reasons: (1) METABRIC
provided disease-specific survival (DS), which considers only breast cancer
death (BC-based death), rather than all causes of death [13]. By contrast,
OSLO provides “overall survival”, which does not distinguish BC-based
deaths from others. As DS is clearly better for our purpose, it is better to
3 http://firebrowse.org/?cohort=KIPAN&download dialog=true
4 https://www.synapse.org/#!Synapse:syn1688369/wiki/27311
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evaluate on the METABRIC dataset. (2a) OSLO and METABRIC
contained different sets of probes – and in particular, OSLO contains only
∼ 80% of the METABRIC probes. (2b) Similarly, the OSLO dataset is also
missing some of the clinical covariates that are present in the METABRIC
dataset – e.g., menopausal status, group, stage, lymph nodes removed, etc.;
see [3, Table 1]. This means a “METABRIC-OSLO study” would need to
exclude some METABRIC features and some METABRIC probes.
We then used a second independent dataset, to verify the effectiveness
of our “dLDA+MTLR” approach. Here, we did not use OSLO, as we
wanted to explore a different type of cancer, and also use a different
platform, to show that our system could still identify an appropriate (and
necessarily different) set of cancer-topics (c topics). We therefore used the
KIPAN dataset from TCGA (The Cancer Genome Atlas), as it (also)
contains a large number of patients and provides survival information.
Table 1 lists some of the important characteristics of these datasets.
Note that KIPAN contains 15,529 genes, while METABRIC has 49,576
probes. This is because many METABRIC probes may correspond to the
same gene each targeting a different DNA segment of the gene. As
different probes for the same gene might behave differently, we gave our
learning algorithm the complete set of probes. Our results on the KIPAN
dataset show that our approach also works when dealing with gene
expression data from a totally different cancer and platform (here kidney
not breast, and mRNAseq rather than Microarray) – demonstrating the
generality of our approach.
3.1 Training vs Test Data
We apply the same experimental procedure to both datasets (METABRIC
and KIPAN): We partition each dataset into two subsets, and use 80% of
the data for training and the remaining 20% for testing. Both partitions
contain instances with comparable ranges of survival times and comparable
censored-versus-uncensored ratio. When necessary, we ran internal
cross-validation, within the training set, to find good settings for
parameters, etc.
4 Overview of learning and performance
processes
As typical for Supervised Machine Learning systems, we need to define two
processes:
• The learning algorithm, LearnSurvivalModel
LSM[ρ=dLDA; Ψ =MTLR]( [XGE, XCF ], Lbl )
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takes a labeled dataset, involving both gene expression data XGE
and clinical features XCF (and survival-labels Lbl) for many patients,
and computes a Ψ =MTLR survival model W . 5 It also returns the
ρ =dLDA “basis set” β¯GE (here, think of a set of c topic
distributions), and some information about the pre-processing
performed, Ω. See Figure 3
• The performance algorithm, UseSurvivalModel
USM[ρ=dLDA; Ψ =MTLR]( [xGE, xCF ], β¯GE, W, Ω ),
takes a description of an individual (both gene expression xGE, and
clinical features xCF ), as well as the ρ =dLDA basis set β¯GE and the
Ψ =MTLR survival model W (and pre-processing information Ω),
and returns a specific survival prediction for this individual, from
which we can compute that person’s risk score. See Figure 6.
To simplify the presentation, the main text will describe the process at a
high-level, skipping most of the details. Notice these functions are
parameterized by the type of dimensionality reduction ρ and the survival
learner Ψ. This section will especially focus on the novel aspects here,
which are the ρ = dLDA transformation (Section 2.2), which complicates
the ComputeBasis[ρ = dLDA](· · · ) function (Section 4.1.1); and the
Ψ = MTLR algorithm for learning the survival model (Section 2.1.1).
Appendix A summarizes the more standard ρ = PCA approach to
reducing the number of features, and the more standard survival models
Ψ ∈{Cox, RCox}, as well as other details about the learning, and
performance models, in general.
4.1 Learning System LSM
Here, LSM[ρ = dLDA; Ψ = MTLR]( [XGE, XCF], Lbl ) first calls
PreProcess, which fills-in the missing values in the XCF clinical features
(producing X ′CF ), and normalizes the real-valued XGE genetic features,
which is basically computing the z-scores X ′GE, over all of the values. It
then calls ComputeBasis[ρ = dLDA](· · · ) to compute a set of c topics β¯GE
from the gene expression data X ′GE (as well as the other inputs), then calls
UseBasis[ρ = dLDA]( X ′GE, β¯GE ), which “projects” X
′
GE onto this β¯GE to
find a low dimensional description of the genetic information; see Figure 5.
These projected values, together with X ′CF and Lbl, form the labeled
training set given to the Ψ =MTLR learning system, which computes a
5 Many subroutines are parameterized by a dimensionality reduction technique
ρ ∈{dLDA, PCA}, and/or by a survival learning algorithm Ψ ∈{MTLR, Cox, RCox}.
We use notation “Alg[ρ; Ψ]( · )” to identify the specific parameters; hence LSM[ρ=dLDA;
Ψ =MTLR]( [XGE , XCF ], Lbl ) is dealing with the ρ =dLDA encoding and Ψ =MTLR
survival learning algorithm.
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Fig 3. Overview of Learning Process: LSM = LearnSurvivalModel
Uses Ψ ∈ { MTLR, Cox, RCox } for type of learner; ρ ∈ { dLDA, PCA }
for the type of basis; XGE are the gene expression values, XCF are clinical
features for a set of patients, “Lbl” is the set of their (survival prediction)
labels, β¯GE is the basis, of type ρ, based on the instance XGE; W is the
learned survival model, of type Ψ; and Ω is information about the
preprocessing. Each (unrounded) box corresponds to data, whose
dimensions appear around it. Each row is a patient, and each column, a
feature. Each rounded box is a subroutine; here we show the input and
output of each.
survival model W . Here, the LSM process returns the dLDA “basis” β¯GE
and the MTLR-model W . (Further details appear in Appendix A.)
4.1.1 ComputeBasis[ρ = dLDA](· · · ) function
As noted above, the ≈50,000 expression values for each patient is so large
that most standard learning algorithms would overfit. We consider two
ways to reduce the dimensionality. One standard approach, Principal
Component Analysis (PCA), is discussed in Appendix A.4. Here, we
discuss a different approach, dLDA, that uses the Latent Dirichlet
Analysis.
The PreProcess routine computes z-scores X ′GE for the gene
expression values XGE; the ComputeBasis[ρ = dLDA] subroutine then has
to transform those real values to the non-negative integers required by LDA
– moreover, it was designed to deal with word counts in documents where,
in any given document, most words appear 0 times, then many fewer
words appear once, then yet fewer words appear twice, etc. We therefore
need a method for converting the real values into non-negative integers.
This process therefore discretizes the standardized gene expression
values (in X ′GE) into the integers { -10, -9, . . . , -1, 0, 1, . . . , 9, 10 }, by
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Fig 4. Histogram of the normalized Gene Expression values {xji} , from
METABRIC, showing how we descretized them into essentially
equal-width bins. Note the heights are on a log-scale.
The material under the histogram – involving x and y – compare two ways
to compute the discretized Gene Expression Values (dGEV): The top
Enc A discretizes the GEVs into a single count-feature A(·), and the
bottom Enc B discretizes the GEVs into two count-features B(·)
representing over-expression and under-expression, respectively.
mapping each real number to the integer indexing some essentially
equal-sized bins; see Figure 4, and Appendix A.2 for details.
This does map each gene expression to an integer, but this includes
both positive and negative values. Given that over-expression is different
from under-expression, an obvious encoding uses two non-negative integer
values for each gene: mapping +2 to [2 ,0], and −3 to [0, 3], etc. Note that
the range of each component of the encoding will be non-negative integers,
and that most of the values will be 0, then fewer will be 1, etc. – as desired.
However, this does double the dimensionality of representation; i.e., we
now have twice the number of genes: UNDER-‘gene name’ and
OVER-‘gene name’. (Below we call this the Enc B encoding; see also B(·)
at the bottom of Figure 4.) Given that very few values are < −1 (in
METABRIC, over 14% (normalized) expression values were > 1, but less
than less than 0.04% were < −1; recall that heights in Figure 4 are on a
log scale), we considered another option: collapsing the +values and
−values to a single value – so both +4 and −4 would be encoded as 4.
This would mean only half as many features (which would reduce the
chance of overfitting), and would continue to note when a gene had an
exceptional value. (This is the Enc A encoding, which corresponds to the
A(·) at the bottom of Figure 4.) As it was not clear which approach would
work better, our implementation explicitly considered both options – and
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used the training set to decide which worked best; see below.
The standard LDA algorithm also needs to know the number of topics
(here c topics) K to produce. ComputeBasis uses (internal)
cross-validation to find the best value for K, over the range
K ∈ {5, 10, 15, . . . , 150}, as well as encoding technique t ∈ {Enc A,
Enc B} – seeking the setting leading to the Cox model with the best
concordance (on each held-out portion). See Appendix A.2 for details.
After finding the best K∗ and encoding t∗, ComputeBasis then finds the
K∗ c topics on the t∗-encoded (preprocessed) training gene expression data
X ′GE; this is the c topic distribution, β¯GE.
The vertical left-side of Figure 5 gives a high-level description of the
ComputeBasis[ρ =dLDA] process: given a large set of (preprocessed)
high-dimensional gene expression profiles, produce a small set of c topics
(each corresponding to a mapping from the gene expression profiles). We
will later describe the UseBasis[ρ =dLDA] process that uses those c topics
to transform the high-dimensional gene expression profile of a novel
instance, into a small dimensional set of values – see the left-to-right
“Performance Process” part here. At this abstract level, it is easy to see
that it nicely matches the ρ =PCA process, where ComputeBasis[ρ =PCA]
would find the top principle components of the X ′GE datasets (here, the
β¯GE box would be those components), which UseBasis[ρ =PCA] could then
use to transform a new gene expression profile into that low-dimensional
“PC-space”.
4.2 Performance system, USM
As shown in Figure 6, the
USM[ρ =dLDA;Ψ =MTLR]( [xGE, xCF ], β¯GE, W, Ω ) system applies the
learned Ψ =MTLR model W , to a PreProcess’ed description of a novel
patient, [x′′GE, x
′
CF ], whose gene expression values x
′′
GE have been
“projected” into the relevant basis β¯GE by UseBasis[ρ =dLDA]. This
produces a survival curve, which it then uses to produce that patient’s
predicted risk score: the negative of the expected time for this distribution,
which corresponds to the area under its survival curve.
Each of the various subroutines are described in an appendix:
PreProcess’, UseBasis[ρ =dLDA] and UseBasis[ρ =PCA] are described in
Appendices A.1, A.3 and A.4, respectively. The UseModel[Ψ =Cox] and
UseModel[Ψ =RCox] produce standard risk scores for each patient ,
obtained by applying the learned Cox (resp., RCox) model to the patient’s
clinical and gene expression features; see Appendix A.5.
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Fig 5. The ComputeBasis[ρ =dLDA] process (shown top-to-bottom, on
left) uses a set of high-dimensional gene expression vectors X ′GE from
many patients, to produce a set of basis vectors (corresponding the
parameters of the LDA) β¯GE. The UseBasis[ρ =dLDA] process (shown
left-to-right horizontally) uses the set of dLDA “basis vectors” β¯GE to
transform a gene expression vector x′GE from a novel patient, into a
low-dimensional description x′′GE. (Note ComputeBasis[ρ =dLDA] also uses
other information, X ′CF and Lbl, to determine the number K of basis
vectors; to simplify the figure, we did not show this.)
5 Experimental Results
As noted above, we intentionally designed our learning and performance
systems (Figures 3 and 6) to be very general – to allow two types of basis
ρ ∈ { dLDA, PCA } and three different survival prediction algorithms
Ψ ∈ {MTLR, Cox, RCox }. This allows us to explore 2× 3 frameworks, on
the two different datasets (METABRIC and KIPAN). For each, the learner
uses internal internal cross-validation to find the optimal parameters.
Below we report the results of each optimized model on the held-out set,
focusing on the Concordance Index (CI) – a discriminator measure. We
also discuss a calibration measure of these results; see Appendix B.2.
We also present our experimental results from the BCC Dream
Challenge winner’s model [13]. As discussed in Section 4.1.1,
ComputeBasis[ρ =dLDA] ran internal cross-validation on the training set to
determine the appropriate encoding t∗ ∈ {Enc A, Enc B} and the optimal
number of c topics for the dLDA model K∗ from a large potential values
(see Algorithm 1 in Appendix A.2). Our experiments found that the
discretization t∗ = Enc B, along with K∗= 30 c topics, produced the best
dLDA algorithm for survival prediction in METABRIC; after fixing the
encoding scheme as Enc B, we used the same technique on the KIPAN
dataset and found K= 50 c topics to be the best. We used the C
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Fig 6. Overview of Performance Process, USM = UseSurvivalModel.
xGE and xCF are the gene expression values and clinical feature values, for
a single patient; see also terms ρ, Ψ, Ω, β¯GE, W from Figure 3.
implementation from Blei et al. [17]6 to compute the c topics. On a single
2.66GHz processor with on 16Gb memory, a single fold takes around ∼20 –
30 hours (more time for larger K). We, of course, parallelized each CV
fold.
We experimented with different combinations of the features from three
groups: (1) clinical features, (2) SuperPC+ principle components
(ρ =PCA), and/or (3) the dLDA c topic (ρ =dLDA); and with three
different survival prediction algorithms Ψ ∈ { Cox, Cox, MTLR }. Our
goal in these experiments is to empirically evaluate the performance of the
survival models that use various types of features. Given this goal, we
evaluate the performance using different GE basis methods (ρ) by
comparing their performance to a baseline model that only uses the clinical
features with Cox [26]. The other combinations include clinical features as
well as various different GE features; each is trained using each of the three
aforementioned survival prediction algorithms (Ψ).
As an additional feature selection step, we removed the covariate “Site”
from the METABRIC clinical covariates, based on our experimental results
(on the training data) that shows its inclusion led to worse concordance.
We experimented with a large, but selective, set of model combinations,
to answer our major queries:
(i) does adding GE features improve survival prediction?
(ii) which is the best feature combination for
survival prediction?
6https://github.com/blei-lab/lda-c
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Table 2. Concordance results of various models from METABRIC (over 395 test
instances) and KIPAN (over 176 test instances).
+ = used these features and − = did not use these features
As PAM50 is specific to breast cancer, it is not applicable to the kidney (KIPAN) data.
The first row, with the ID “A(*)”, is the baseline.
ID Feature Groups Learning Alg. Concordance
Clinical PCA dLDA PAM50 Cox | RCox | MTLR METABRIC KIPAN
A (*) + − − − Cox 0.6810 0.7656
A + − − − RCox 0.6883 0.8156
A + − − − MTLR 0.6820 0.8207
B + + − − Cox 0.6961 0.7691
B + + − − RCox 0.7048 0.8196
B + + − − MTLR 0.6999 0.8232
C + − + − Cox 0.7073 0.7638
C + − + − RCox 0.7108 0.8332
C + − + − MTLR 0.7139 0.8482
D + + + − Cox 0.7074 0.8062
D + + + − RCox 0.7145 0.8401
D + + + − MTLR 0.7079 0.8495
E + + + + Cox 0.7075 NA
E + + + + RCox 0.7172 NA
E + + + + MTLR 0.7202 NA
F + Meta-Genes Ensemble Model 0.7293 NA
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Fig 7. Test CI: METABRIC (left) and KIPAN (right). Note higher values
are better. The labels on the x-axis correspond to Table 2.
(iii) which is better representation of the GE features: dLDA or
SuperPC+?
(iv) are we deriving GE features that are redundant with PAM50?
Our results appear in Table 2, shown visually in Figure 7(left). These
lead us to claim:
(i) Comparing the baseline, A-Cox7, to the other models, we
immediately see that adding GE features (using any of the dimensionality
reduction technique) leads to better predictive models; – i.e., all of the
results are better than A-Cox’s CI of 0.6810 (the left-most light-shaded bar
in Figure 7(left) ).
(ii) The best model for METABRIC is the one that includes all of the
types of features derived from the gene expression – here E-MTLR, which
is the right-most bar of Figure 7(left).
We also performed student’s t-tests on random bootstrap samples from
the test data to validate the significance of our results. When we compare
this best model, E-MTLR, against models B-RCox (which is the best
model using only PCA GE features) and C-MTLR (the best model using
only dLDA GE features), we find statistically significant difference
between them (respective pairwise p-value: 4.8e-16, 1e-3), showing that the
E-MTLR model is significantly better than its closest counterparts.
(iii) These empirical results show that, if you are pick only a single GE
feature set, the dLDA c topics perform better than the principle
components – that is, the C-χ has a higher score than B-χ, for χ ∈ {Cox,
RCox, MTLR}; moreover, a model using both sets of features performs yet
better (i.e., D-χ is better that C-χ).
(iv) Comparing the D-χ to E-χ, we see that adding PAM50 subtypes as
features to the METABRIC database improves the held-out test
concordance.
7To explain this notation, the ‘A’ refers to the feature set used, which here is the far
left triplet of blocks in Figure 7(left); the ‘Cox’ refers to the learning algorithm, which
appears left-most in each triplet. See also Table 2.
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Indeed, we see that the performance of models that include PAM50 are
marginally better than similar models that do not (row D), suggesting that
the information added by these different representations of GE data are
not redundant. Moreover, we see that, in all feature groups, both RCox
and MTLR clearly outperform Cox – i.e., ν-RCox and ν-MTLR are better
than ν-Cox, for ν ∈ {A,B,C,D,E}. We then tested the first three claims on
the KIPAN dataset; see Table 2 (right-most column) and Figure 7(right).
(As KIPAN does not deal with breast cancer, the PAM50 features are not
relevant, so we could not test claim (iv).)
(i) As before, we found that adding expression information improves
over the baseline A-Cox – i.e., essentially all values are better than 0.7656.
(ii) We again found that the best model was the one that included all of
the features; here D-MTLR. Moreover, a t-test on bootstrap replicas show
that this model D-MTLR was significantly better than the top model that
does not include dLDA features, B-MTLR.
(iii) We again see that C-χ has a higher score than B-χ, meaning
(again) that models trained with only the c topics performed much better
than PCA-features ; but that including both features was yet better (D-χ).
These sets of experiments support our claim that
a model learned by running MTLR on all GE features,
gives very good concordance scores
– statistically better than other options in two different datasets, using
different platforms, related to different cancer types.
In addition to these evaluations using the discriminative concordance
measure, we also applied a calibration measure: “D-Calibration” (“D” for
“Distribution”) [15,16], which measures how well a individual survival
distribution model is calibrated, using the Hosmer-Lemeshow (HL) [30]
goodness-of-fit test; see Appendix B.2. We found that all of our models,
for both datasets (METABRIC and KIPAN), passed this calibration test;
see Appendix C.2, especially Table 3. But we have found that this is not
universal. For example, we experimented with another breast cancer
dataset BRCA (results not shown here), and found that the Cox model
failed for all configurations (of ρ), showing that the Cox model does not
always produce calibrated results – here, for situations where RCox and
MTLR produced D-calibrated predictors. See also Haider et al. [16].
5.1 Other Comparisons
In 2012, Cheng et al. [13] won the BCC Dream Challenge (which was
based on the METABRIC data) by (i) leveraging prior knowledge of cancer
biology to form Meta-Genes and (ii) training an ensemble of multiple
learners, fueled by the continuous insights from the challenge competitors
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via open sharing of code and trained models. To compare our
performances with this BCC winning program, we reproduced their models
(using the DreamBox7 package), then re-trained their ensemble learners on
our training split of the METABRIC data and tested on the held-out test
set. Table 2[Row F] shows that the resulting ensemble model achieved a CI
of 0.7293 on the test data. While that score is slightly better than the
performance of our best model (Table 2[Row E]), note that all of our
tuning was performed solely on the training (n=1586) data, while their
team made major design choices for their model using the entire
METABRIC cohort (all n=1981 instances), on which it was then evaluated.
Recently, Yousefi et al. [31] trained a deep neural network on this
KIPAN data – including this gene expression data, as well as other
features: Mutation, CNV and Protein. They reported concordance scores
around 0.73 − 0.79, which are lower than our best, 0.8495 .
Finally, while we focused on the LDA approach, we also explored
another topic modeling technique, Latent Semantic Indexing (LSI) [23].
Running this on both datasets (using the same discretization approach, the
same t∗ = Enc B encoding and the same number of c topics, K∗ = 30), we
found essentially the same Concordance values, and confirmed that all four
claims (i) through (iv) still hold, just replacing dLDA with the “discretized
LSI” (dLSI) encoding.
6 Discussion
Given the growing number of gene expression datasets as part of survival
analysis studies, it is clearly important to develop survival prediction
models that can utilize such high-dimensional GE data. This motivated us
to propose a novel survival prediction methodology that can learn
predictive features from such GE data – exploring ways to learn and use
c topics as features for models that can effectively predict survival. N.b.,
this paper focuses exclusively on this predictive task, as this can lead to
clinically relevant patient-specific information; indeed, this motivated the
BCC Dream challenge, which provided the METABRIC dataset. We
anticipate future work will explore the possible interpretation of these
c topics.
We included Cox as one of our learning modules for this task as it is
known to be effective at optimizing concordance, both empirically and
theoretically [32]. We included RCox as this algorithm recently won
Prostate Cancer Dream Challenge 9.5 [12]. Finally, we included the MTLR
survival prediction model as its performance, there, was competitive with
the best, as well as based on the empirical evidence in Haider et al. [16].
Our evaluations on these two datasets show that MTLR’s performance was
often better than RCox and Cox. Moreover, while the basic RCox and Cox
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functions produce only a risk score for each patient, MTLR provides a
survival distribution for each, mapping each time to a probability; see
Figure 2. Such models, which produce an individual survival distribution,
can be used to compute a risk score, allowing them to be used for
concordance-tasks; they can also be used to predict single time
probabilities (e.g., probability of a patient living at least 3 years), and also
can be visualized.8
To summarize the main disadvantages and advantages of our approach,
versus more standard approaches (e.g., PCA for dimensionality reduction,
and (R)Cox for survival prediction):
• Disadvantages:
– Topic models are not simple to describe.
– This approach requires a fairly long training time (∼20 hours
on a 16GB, 2.66GHz processor for a single model) – to first find
the parameters (encoding, number of c topics), then the
c topics themselves, and finally, to learn the model that has the
best performance. (However, using the trained dLDA model to
predict c topic contributions for a new patient is very fast –
under a second on a general purpose laptop computer.)
• Advantages:
– An effective process to learn representation from gene expression
data, as a meaningful probability distribution over the genes.
– The learned representation from the gene expression data
improves survival prediction, over standard methods, in:
∗ Different cancer types: Breast and Kidney.
∗ Different gene expression data types: Microarray and
mRNASeq.
∗ Different survival prediction algorithms: Cox,
Regularized-Cox and MTLR.
– Our combined approach for feature learning and survival
prediction (dLDA + MTLR) archives strong concordance scores
compared to standard survival models across different cancer
types.
8 We did use the Kalbfleisch-Prentice approach to estimate the base hazard function,
allowing Cox and RCox to similarly produce individual survival curves. Appendix B.2
describes a way to evaluate such “individual survival distribution” models, D-Calibration.
Appendix C.2 then shows that, for these datasets, these models all pass this test.
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7 Conclusion
Table 2 shows that our proposed model, which uses MTLR to learn a
model involving various types of derived GE features (dLDA c topics
and/or SuperPC+), has the best concordance, in two datasets representing
different types of cancer, and two different gene expression platforms
(micro-array and mRNAseq). That table shows that adding GE features
improves survival prediction and that including both dLDA c topics and
SuperPC+ principle components gives the most improvements across
held-out datasets . We also found that the “framework” that produced the
best model in METABRIC, was also the best in the Pan-kidney KIPAN
dataset, which shows the robustness of our proposed prediction framework.
Moreover the c topics extracted by our dLDA procedure (inspired by topic
modeling) can be interpreted as collections of over-expressed or
under-expressed gene sets; further analysis is needed to discover and
validate the biological insights from these c topics. Our results show that
our novel survival prediction model – learning a MTLR survival model
based on our derived GE features (dLDA c topics and SuperPC+
components) – leads to survival prediction models that can be better than
standard survival models. We anticipate that others will find this
dLDA+MTLR approach helpful for their future tasks.
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Fig 8. Simplified flow diagram describing the overall prediction process,
including both the learning task and the performance task.
A Details about the Algorithms
Section 4 gave a high-level overview of the important parts of the learning,
and performance, systems; see also Figure 8. This appendix completes that
description. In particular, it summarizes the components of the learning
and performance systems – each shown as a rounded-rectangle in Figures 3
or 6 – roughly in a top-to-bottom fashion. Appendix A.1 describes the
PreProcess(· · · ) routine that preprocesses the training data (both gene
expression and clinical features), and the related PreProcess’(· · · )
routine, used by USM, to preprocess a novel instance. Appendix A.2 then
gives many details about ComputeBasis[ρ =dLDA]( · · · ) that computes the
set of “c topic− genes” distributions, given gene expression values (and
some additional information) – extending the high-level description in
routine in Section 4.1.1. Appendix A.3 describes the UseBasis[ρ=dLDA]
routine that uses these c topic-genes distributions to map each patient’s
gene expression profile into that patient’s specific “c topic - distribution”;
see Figure 5. Appendix A.4 presents ComputeBasis[ρ =PCA] and
UseBasis[ρ =PCA] techniques, to deal with the other approaches for
reducing the dimensionality, PCA. Finally Appendix A.5 describes two
related standard survival analysis methods: Cox [26], and Ridge-Cox
(RCox) [33]. (Section 2.1.1 presented another approach, based on the more
recent MTLR approach to survival analysis.)
A.1 PreProcess and PreProcess’
The PreProcess process (used by LSM in Figure 3) applies various
standard “normalizations” and simple “corrections” to the training data –
both raw clinical features, and gene expression values. For the clinical
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features XCF , PreProcess produces a normalized dataset without any
missing values, ready for the subsequent steps in the pipeline – see the
orange-lines in Figure 3. This uses the standard steps: (1) impute missing
real (resp., categorical) values for a feature with the mean (resp., mode) of
the observed values for that feature; and (2) binarizing each categorical
variable (aka “one-hot encoding”) – e.g., we encoded the 12-valued
“Histological type” using twelve bits: e.g., Invasive Tumor is [1, 0, 0, 0, 0, 0,
0, 0, 0, 0, 0, 0]. For the gene expression data XGE, PreProcess applies
the following steps: (1) As we want to deal with the log of the initial gene
expression value, we first log2-transformed the data, if necessary. (Below
we use “gene expression” to refer to this transformed value.) (2) Then
translate all expression values into their “common z-scores”. It first
computes the (common) mean and standard deviation over all the genes
from the entire XGE dataset: Let e
j
i be the expression value of probe/gene
gi of patient j, then compute the common mean µˆ =
1
n
∑
i,j e
j
i (where n =
1,981×49,576 is the total number of entries for METABRIC), and the
variance σˆ2 = 1
(n−1)
∑
i,j(e
j
i − µˆ)2. We then use the Z-score transformation
of each entry: zji =
(eji−µˆ)
σˆ
. Notes: (a) this standardization is done prior to
dividing the data into train and validation sets. (b) Using z-scores based
on only a single gene would not be able to identify which genes did not
vary much, as (after this transform) all genes would vary the same amount.
(3) PreProcess then removes the genes that do not vary much, removing
a gene i iff its zji values are all within the first standard deviation – i.e., if
∀j zji ∈ [−1,+1].
This filtering process is motivated by the assumption that any gene
whose expressions does not change much across multiple patients, is
unlikely to be directly related to the disease, while the genes that
contribute, typically have significant variations in their expression levels
across patients. While this filtering procedure is unsupervised, we
anticipated that it would retain the genes that have the most prognostic
ability. This was confirmed as we found that this process does not
eliminate any of the “top” 100 probes in the METABRIC data (these are
the probes with the 100 highest concordance values); see [13, Table 1]. In
METABRIC, this filtering procedure eliminates 27,131 of the original
49,576 probes, leaving only 22,445 probes – i.e., a ≈54.7% reduction in the
number of features.
Later, the performance system USM will need to apply these
pre-processing steps to a novel instance – in particular, for each clinical
feature, it will need to know the mean (or median) value, for imputation.
Similarly, it will need to transform each gene expression values into an
integer; this requires knowing the global mean µˆ and σˆ2 values to produce
the z-values {zji } values, We include all of these values in the Ω term,
which is output by the PreProcess subroutine. This Ω is one of the
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Algorithm 1 ComputeBasis[ρ=dLDA] algorithm
1: function ComputeBasis[ρ =dLDA]( X′GE , X
′
CF , Lbl ) . Returns a set of c topics
2: X′′GE := Discretize( X
′
GE )
3: for t in { Enc A, Enc B } do
4: GEt := Encode-GE( t, X′′GE )
5: [GEt,1, GEt,2, . . . , GEt,5] := Partition( GEt )
6: % Notation: GEt,−i = GEt − GEt,i
7: % X′CF,i = clinical features;
8: for K in (5, 10, 15, . . ., 150) do
9: for i = 1:5 do
10: % Find LDA "basis set" (set of c topics)
11: β¯t,K,i := Compute dLDA( GEt,−i, K )
12:
13: % Project the hold-out set onto this basis set,
14: % encoding each patient as a K-tuple of values
15: GE Topict,K,i := Use dLDA( GEt,i, β¯t,K,i )
16:
17: % Learn a Cox model for this encoding, value of K, and fold i
18: % using both c topics and the clinical features
19: % LearnCox & PredictCox are based on [26]
20: wt,K,i := LearnCox( [GE Topict,K,i, X′CF,i ], Lbli )
21:
22: % Evaluate model on the hold out set
23: % Using evaluation measures concordance and likelihood
24: ct,K,i := Concordance( PredictCox( wt,K,i, [GEt,i, X′CF,i]), Lbli )
25: lt,K,i := Average{ Likelihood( β¯t,K,i, GEt,i ) }
26:
27: c¯t,K := Average{ ct,K,i }
28: l¯t,K := Average{ lt,K,i }
29:
30: % Find t∗ (encoding scheme), with the highest concordance
31: t∗ := argmaxt{ c¯t,K }
32: % Selecting K∗
33: Kˆ = argmaxK(l¯t∗,K)
34: K∗ = arg maxK s.t. l¯
t∗,Kˆ − σˆ(lt∗,Kˆ) ≤ l¯t∗,K {c¯t∗,K} % Break ties giving priority to
small K’s
35:
36: return Compute dLDA( GEt∗ , K∗ )
inputs to the PreProcess’ process, within USM, which applies these
pre-processing steps to a novel instance encoded by its xGE and xCF
features. Note finally that neither PreProcess nor PreProcess’ use
the labels (survival times).
A.2 ComputeBasis[ρ =dLDA]
As shown by the blue lines in Figure 3, the ComputeBasis process takes
as input a pre-processed version of the labeled dataset that was input to
LSM: the PreProcessed gene expression data X ′GE and clinical features
X ′CF , with their associated labels (Lbl). This process produces the “basis”
set, of type ρ. This subappendix will focus on ρ = dLDA.
As shown at the bottom of Algorithm 1, ComputeBasis returns the
results of Compute dLDA( GEt∗ , K
∗), which are a set of K∗
c topic–distributions, based on its input GEt∗ , which encodes the gene
expression values (X ′GE) as non-negative integers. This means
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ComputeBasis must first (1) transform its input real-valued gene
expression values X ′GE into non-negative integers GEt∗ , and (2) determine
the appropriate number of c topics K∗ ∈ Z+ . Task (1) has two parts:
(1a) Line 2 first discretizes the real-valued XGE into (positive and negative)
integers Z. (1b) The next part of the subroutine determines the best way
to transform those integers into non-negative integers Z≥0. Below we
describe these three steps, followed by (3) a description of
Compute dLDA.
(1a) Discretize subroutine
Recall first that the PreProcess routine already translated the
real-valued XGE gene expression values into z-scores X
′
GE, and excluded
every genes whose values here all were in (−1, +1). To simplify the
notation, view X ′GE = {zji }. The Discretize routine first assigns each
zji ∈ (−1, 1) to 0. For the remaining “non-trivial” standardized gene
expression values zji ’s (outside the first standard deviation) of each gene:
Letting Z+i = { zji | zji ≥ 1 } be the non-trivial positive values, we divide
∆+i = max{Z+i } − min{Z+i } into 10 regions, of size ∆+i /10 each and
identify each positive zji with the index ∈{ 1, 2, . . . , 10} of the
appropriate bin. We similarly divide the non-trivial negative expression
values Z−i = {zji | zji ≤ −1 } into their 10 bins, based on
∆−i = max{Z−i } −min{Z−i } and each negative zji is identified with the
index ∈{ -1, -2, . . . , -10} of the appropriate bin; see Figure 4. (Of course,
the actual divisions are specific to the different genes; this figure just
shows a generic split.) In general, we let bji be the integer bin index
associated with gene gi for subject j.
9
(1b) Transform to Non-Negative Integers
While Discretize mapped each gene expression value zji to an integer b
j
i ,
the Compute dLDA routine requires non-negative values. Section 4.1.1
discussed two ways to deal with this: using either encoding Enc A versus
Enc B; see bottom of Figure 4. ComputeBasis uses internal
cross-validation to determine which of these is best, t∗, along with the
number K∗ of c topics; see below. (In general, we will let GEt refer to the
t-encoding of the gene expression values.)
91. We initially tried to discretize the values into the bins associated with the standard
deviation, in general. However, we found this did not work well.
2. ComputeBasis also returns these {∆+i ,∆−i }i values, as part of the encoding – i.e.,
along with β¯GE – and UseBasis will later use this information to discretize its real-
valued gene expression input. We did not show this detail, to avoid overcluttering the
text and images.
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(2) Finding Optimal K∗, t∗
As noted, the Compute dLDA algorithm also needs to know the number
of c topics K∗ to produce. Rather than guess an arbitrary value,
ComputeBasis instead uses (internal) cross-validation to find the best
value for K, over the range K ∈ {5, 10, 15, . . . , 150}. For each technique
t ∈ {Enc A, Enc B} and each of the 30 values of K, ComputeBasis first
computes the dLDA model over the training set, using Compute dLDA
(for that encoding and number of c topics); it then used these and the
(preprocessed) clinical features (X ′CF ) as covariates, along with the survival
labels Lbl, to learn a Cox model [26] – see Algorithm 1, lines 9–20. Note it
does this in-fold – using 4/5 of the training set to learn the dLDA c topics
and the Cox model, which is evaluated by computing the concordance
(based on this learned model) on the remaining 1/5 (line 24).
As noted above, we need to determine (1b) which is the best
discretization t∗, Enc A or Enc B, and (2) what is the appropriate K∗ for
that technique. To answer the first question, ComputeBasis picked the
encoding technique t∗ that gave the highest cross-validation concordance
from all the (30× 2) combinations (see Algorithm 1, line 31). Secondly,
after deciding on a encoding scheme, it sets Kˆ to be the value with the
largest (cross-validation) likelihood, then selects the set of K’s that are
smaller than Kˆ and whose cross-validation likelihood scores are within the
first standard deviation of the Kˆ’s; see Algorithm 1, line 33. From these
candidates, it selected the K∗ that gives essentially the highest
concordance (see Algorithm 1, line 34). Empirically, we found that the
internal cross-validation concordance scores was fairly flat over the critical
region – e.g., K ∈ {20, .., 35} for METABRIC – before dipping to smaller
values for larger value of K, presumably due to overfitting. This is why we
are confident that the upper limit, of 150 topics, is sufficient. Once it
finds the best K∗ and the encoding technique t∗, ComputeBasis then
runs Compute dLDA on the t∗-encoded (preprocessed) training gene
expression data GEt∗ , seeking K
∗ c topics; this is β¯GE “basis”. This
routine also returns the {∆±i } values used to produce the discretized
values, GEt.
(3) Compute dLDA
The Compute dLDA( GEt, K) process, based on Blei et al. [17],
computes K c topics, based on the preprocessed, discretized gene
expression data GEt, as well as the number of latent c topics K; it then
returns K c topics–distributions, each ≈50,000-parameters of the Dirichlet
distribution (for METABRIC), corresponding to a line of the β¯GE shown in
Figure 5. (Each point here corresponds to its estimate of the posterior
βGE, conditioned on the observed gene expression values.) This routine
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also uses the Dirichlet prior for the patient–c topics distribution; here we
used the symmetric Dirichlet(α, . . . , α) for some α ∈ <>0. (As there are K
c topics; we view this as a vector α1K .) We experimented with several
values α ∈ {0.01, 0.1, 0.5, 1.0}, but found that the prior did not make
much difference, since we allowed the model to estimate the prior
internally. We therefore set α = 0.1.
This routines also needs to set the priors for the K different
c topic–gene expression distributions β
(∗)
GE[i, :] = [β
(∗)
GE[i, 1], . . . , β
(∗)
GE[i, N ]],
for i = 1..K, each sweeping over the N genes. Here, we use the prior
β
(∗)
GE[i, j] =
1
N
+ δ where δ ∼ U [0, 1/N2] – i.e., δ is sampled from the
uniform distribution over the interval [0, 1/N2]. This LDA learning
process [17] uses the data in GEt to compute the posterior distribution
{ βGE[i, :] }i for each of these K c topics – revealing GEt’s intrinsic
structure. Recall these are just the parameters for Dirichlet distribution;
note they must be positive, but do not add up to 1. The Compute dLDA
returns the expected values of the gene expression values drawn from this
posterior distribution: β¯GE[i, j] =
βGE [i,j]∑
j′ βGE [i,j′]
. Here, the probability
values for each c topic β¯GE[i, :] add up to 1. We will let β¯GE = {β¯GE[i, :]}
refer to the entire “matrix”.
A.3 UseBasis[ρ =dLDA]
Once LSM has learned the c topics (β¯GE) for the best K
∗ and best
encoding technique t∗, we can then compute the c topic distribution for a
new patient (based on her gene expression xGE); see Figures 3 and 6. This
will call UseBasis, which in turn runs Use dLDA (the LDA inference
procedure) on the preprocessed gene expression data x′GE of the current
patient to compute the individual topic contributions for this patient [17].
The inference procedure determines the posterior distribution of the
patient-c topic Dirichlet distribution
Θ(x′GE) = [ θ1(x
′
GE), θ2(x
′
GE), . . . , θK∗(x
′
GE) ] ∈ <K∗+ , where each
θj(x
′
GE) ∈ <+ quantifies how much of this patient’s gene expression is
from the jth c topic (using the posterior mean probabilities of the c topics,
β¯GE).
This process reduces the ≈20 000-dimension gene expression values to a
very small K∗-dimensional c topics representation – e.g., L∗ = 30. These
low-dimensional feature vectors are then used in the survival prediction
algorithms to predict survival times/risk.
A.4 ComputeBasis[ρ =PCA] and UseBasis[ρ =PCA]
The previous subappendix described one way to reduce the dimensionality
of the data – to transform each patient’s 20,000-tuple to a more
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manageable K-tuple – there based on topic modeling ideas. There have
been many other feature selection methods proposed for survival prediction
using gene expression data, such as hierarchical clustering, univariate gene
selection, supervised PCA, penalized Cox regression and tree-based
ensemble methods [34]. Some of these techniques first apply a procedure to
reduce the dimensionality of the data, based on feature selection, feature
extraction or a combination of both, while others, such as random survival
forests [9] and L1-penalized Cox [35], include internal feature selection. As
we wanted to compare our dLDA approach to other dimensionality
reduction techniques, we chose an extension to the principle component
analysis called supervised principal component analysis (SuperPC) [36],
instead of other regularization techniques.
This algorithm first calculates the univariate Cox score statistic of each
individual gene against the survival time, then retains just the subset of
genes whose score exceeds a threshold, determined by internal
cross-validation. Then it computes PCA on the dataset containing only
those selected genes, then projects each patient onto the first one (or two)
components. The main disadvantage of the SuperPC algorithm is that the
individual genes selected from the univariate selection process might not
perform the best in a multivariate (final) model, perhaps because many of
these top-ranked genes may be highly correlated with one another – i.e., it
would be better having a more “diverse” set of genes [34,37]. Instead, we
use a variant, called SuperPC+, that initially applies PCA on the
normalized gene expression data after the constant genes are removed; see
PreProcess in Appendix A.1). The PCA transformation projects the
initial “raw” features into a different space, which then can be used to
select the top components based on the univariate Cox regression. Note
this SuperPC+ is (still) computationally efficient, as it is based on PCA,
which is efficient: Even though gene expression data is high dimensional
(p n, where p is the number of genes and n is the number of instances),
the rank of the GE matrix will be (at most) min{p, n} = n. Therefore,
PCA can be performed without many computational restraints on the
whole gene expression dataset, as here the PCA time complexity is O(n3).
After performing PCA on the GE dataset, we can then identify the most
important principal components by computing a Cox score statistic for the
univariate association between each principal component and the survival
time. In our experiments, we select the threshold η for the p-value of the
Cox score by internal cross-validation (wrt concordance), and retained all
PCs having a p-value lower than this η – finding η =5e-4 for the
METABRIC dataset and η =5e-2 for KIPAN. These selected PC
components form the basis set BGE[ρ =PCA].
UseBasis[ρ =PCA] is simply the projection of the gene expression data
into the chosen PC components. This gives us a low dimensional feature
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representation of the original gene expression data to feed into the survival
prediction algorithms.
A.5 Cox Models: LearnModel[Ψ =Cox],
LearnModel[Ψ =RCox]
The Cox regression model’s [26] hazard function over time t, for an
individual described by x, is the product of two components:
hW ( t |x ) = h0(t)× exp(xTW ) (3)
where the baseline hazard h0(t) is independent of the covariates x and the
covariates are (independently) multiplicatively related to the hazard, based
on a (learned) W . This formulation simplifies modeling of the hazard
function by limiting the contribution of the “time” variable t to the
baseline hazard h0(·), which means the hazard ratio (HR) between two
patients
HR(x1, x2) =
h( t |x1 )
h( t |x2 ) =
h0(t) exp(x
T
1W )
h0(t) exp(xT2W )
= exp((x1 − x2)TW )
does not depend on time and is linear (proportional) in the exponent. To
estimate the coefficients of the model, Cox [26] proposed a partial
likelihood technique that eliminates the need to estimate the baseline
hazard. This procedure allows the Cox proportional hazards model to be
semi-parametric, by only using the survival times to rank the patients [32].
We can compute partial likelihood with all patients – both censored and
uncensored:
Lc(W ) =
N∏
i=1
(
exp(xi
TW )∑
k∈R(yi) exp(xk
TW )
)δi
(4)
• R(yj) is the risk set at time yj, which are the indices of individuals
who are alive and not censored before time yj
• [xi, yi, δi] describes the ith subject, where
xi = vector of covariates
yi = (survival or censor) time
δi = censor bit (0 for censored; otherwise 1)
• N – total number of patients in the cohort
• W – coefficients (to be learned)
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Note that only the uncensored likelihoods contribute directly, since for
censored instances δi = 0. Therefore the censored observations are only
utilized in the denominator when summed over the instances in a risk set.
In essence, the partial likelihood only uses the patient’s death times to
rank them in the ascending order to find the risk sets and does not use the
exact times explicitly [32]. Hence, the coefficients estimated by maximizing
the partial likelihood depend only on the ordering of the patient’s death
times and the covariates, allowing for an implicit optimization for good
concordance of the risk score. An in-depth study on the Cox proportional
hazard model has revealed that the partial likelihood proposed by [26] is
approximately equivalent to optimizing concordance [32].
There are several extensions of the basic Cox proportional hazards
model: some extend the initial model estimating the baseline hazard and
others are based on the regularization methods imposed on the coefficients
(W ). Generally, regularization based on LASSO, ridge penalty or the
elastic-net regularization (which allows both L1 and L2 penalties) are
adopted to reduce overfitting. In our work, we use the glmnet R
package [33] with ridge penalty (by setting α = 0 in the glmnet function);
here called RCox. We selected ridge penalty based on the internal cross
validation. We found that concordance results using models with ridge
penalty were better than those having no regularization (LASSO,
elastic-net).
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B Foundations
B.1 Evaluation: Concordance Index (CI)
This “CI” evaluation applies to any model that assigns a real number – a
“risk score” – to each instance f(·). It considers all pairs of “comparable”
instances, and determines which is predicted (by the risk model f(·)) to
die first, and also who actually died first. CI is the proportion (probability)
of these pairs of instances whose actual pair-wise survival ordering,
matches the predicted ordering, with respect to f(·):
CI(f) =
1
|Ψ|
∑
(i,j)∈Ψ
I[ f(xi) > f(xj) ] (5)
where I[φ] is the indicator function, which is 1 if the proposition φ is true,
and 0 otherwise. A pair of patients is “comparable” if we can determine
which died first – i.e., if both are uncensored, or when one patient is
censored after the observed death time of the other; this corresponds to
the set of ordered pairs of indices Ψ. This CI(f) score is a real value
between 0 to 1, where 1 means all comparable pairs are predicted correctly.
CI can be viewed as a general form of the Mann–Whitne–Wilcoxon
statistic and is similar to the Area Under the ROC (Receiver Operator
Curve), AUC, of classification problems [32].
B.2 Evaluation: D-calibration
The concordance index is a discriminatory measure, which is relevant, for
example, when deciding which patient with liver failure will die first
without a transplant. By contrast, calibration measures the deviation
between the observed and the predicted event time distributions. While
this is not meaningful if we only have a risk score (e.g., as produced by the
basic Cox Proportional Hazard function), this deviation can be computed
for a survival distribution, like ones produced by the MTLR survival
prediction tool, or the Cox+KF system – which extends the standard Cox
model by using the Kalbfleisch-Prentice estimator to produce the baseline
hazard function h0(x) in Equation 3; see [11]. In general, this calibration
involves computing the difference between the predicted versus observed
probabilities in various subgroups – e.g., if the predicted probability of
surviving at least t =2576 days is 0.75 for some subgroup, then we expect
to observe around 75% of these patients to be alive at this time t.
We consider a novel measure of the calibration of such survival curves,
called D-calibration (“D” for “Distribution”) [16]. To motivate this,
consider a standard Kaplan-Meier (KM) [8] plot shown in Figure 9, which
plots the set of points (t, KM( t ) ) – i.e., it predicts that the KM( t )
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Fig 9. Kaplan–Meier survival function from METABRIC (training) data.
(We only use the quartiles for pedagogic purposes)
fraction of patients will be alive at each time t ≥ 0. Hence, the point
(6184 days, 0.50) means the median survival time of the cohort is
6184 days; see Figure 9(solid line). We will use KM−1( p ) to be the time
associated with the probability p – technically, KM−1( p ) is the earliest
time when the KM curve hits p; hence KM−1( 0.5 ) = 6184 days. If this
plot is D-calibrated, then around 50% of the patients (from a hold-out set,
not used to produce the KM curve) will be alive at this median time. So if
we (for now) ignore censored patients, and let di be the time when the i
th
patient died, consider the n values of {KM( di ) }i=1..n. Here, we expect
KM( di ) > 0.5 for 1/2 of the patients. Similarly, as the curve includes
(2576 days, 0.75) and (8941 days, 0.25), then we expect 75% to be alive at
2576 days, and 25% at 8941 days; see Figure 9. Collectively, this means we
expect 25% of the patients to die between KM−1( 1.0 ) = 0 days and
KM−1( 0.75 ) = 2576 days, and another 25% between KM−1( 0.75 ) and
KM−1( 0.5 ), etc. These are the predictions; we can also check, to see how
many people actually died in each interval: in the first quartile (between 0
and 2576 days), in the second (between 2576 and 6184 days), in the third
(between 6184 and 8941 days), and the fourth (after 8941 days). If the KM
plot is “correct” – i.e., is D-calibrated – then we expect 1/4 of the patients
will die in each of these 4 intervals. The argument above means we expect
1/4 of the {KM( di ) } values to be in the interval [0, 0.25], and another
quarter to be in [0.25, 0.5], etc. Stated more precisely,
the values of {KM( di ) } are uniformly distributed. (6)
A single KM curve is designed to represent a cohort of many patients.
The MTLR system, however, computes a different survival curve for each
patient – call it Pri( · ) = PrW ( · | xi ) (from Equation 1). But the same
ideas still apply: Each of these patients has a median predicted survival
time – the time Pr−1i (0.5) where its Pri( · ) curve crosses 0.50.
By the same argument suggested above, we expect (for a good model
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W ) that 1/2 of patients will die before their respective median survival
time – di ≤ Pr−1i (0.5); that is, |{i : Pri(di) ≤ 0.5}| ≈ n/2. Continuing the
arguments from above, we therefore expect the obvious analogue to
Equation 6:
the values of {Pri( di )} are uniform. (7)
We can now test whether a model is D-calibrated by using the
Hosmer-Lemeshow (HL) [30] goodness-of-fit test, which compares the
difference between the predicted and observed events in the event
subgroups:
HL
  [N1, P1, E1]· · ·
[NG, PG, EG]
 = G∑
g=1
(Eg − Pg)2
Ngpig(1− pig) (8)
where G is the number of subgroups (here 4), where the gth subgroup has
Ng ∈ Z+ events, with the empirical number of events Eg ∈ Z+ (which here
is N/g, for N =
∑
gNg total patients), the corresponding predicted
number of events in each group Pg ∈ Z≥0, and pig = NgN (which here is 1G)
is the proportion of the gth subgroup. Under the null hypothesis
(Equation 7), this HL statistics follows a Chi-Square distribution with
G− 2 degrees of freedom. If the predicted and empirical event rates are
similar for the subgroups, the test statistic will fail to reject the null
hypothesis, providing evidence that the model’s predictions are well
D-calibrated – i.e., large p-values from the test statistic suggest not
rejecting the null hypothesis).
Notes: (1) This evaluation criterion only applies to models that produce
survival distributions, which means it directly applies to the MTLR
models. For the Cox and RCox models, we used the Kalbfleisch-Prentice
baseline hazard estimator [11] to produce personalized survival curves.
(2) To provide more precise evaluation, rather than using 4 bins
(quantiles), we mapped the Pri( di ) probabilities into 20 bins: [0, 0.05);
[0.05, 0.1), . . . , [0.95, 1.0]. (3) This analysis deals only with uncensored
data; Haider et al. [16] discusses how to cope with censored data.
C Additional Results
This appendix presents additional results: First, Appendix C.1 evaluates
the Latent process decomposition (LPD) method, then Appendix C.2
provides D-calibration results of our various models.
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C.1 Latent process decomposition (LPD) for
microarray feature extraction
Rogers et al. [19] introduced LPD as a topic model adaptation for
microarray data. We experimented with LPD (on METABRIC data) to
derive genetic features and used them along with the clinical features for
comparison. We used internal cross-validation for LPD to find the optimal
number of latent processes for the METABRIC data – and found that 10
was best.
We then used the model based on these 10 latent process; the resulting
concordance results, on the hold-out dataset, was 0.6915 (Cox), 0.6077
(RCox) and 0.6995 (MTLR). Comparing this to the “B” and “C” rows of
Table 2, we see that our dLDA approach performs better than this
complex adaptation of the LDA model for microarray data, for the survival
prediction task – i.e., dLDA produces better features from the gene
expression data.
There are two other reasons to prefer our dLDA-approach: (1) LPD has
large time and memory requirements. (2) Moreover as our dLDA directly
uses the LDA model, it can utilize all available off-the-shelf
implementations, across several technology platforms with efficient and
scalable implementation [38].
C.2 D-Calibration Results
Table 3 shows the D-calibration results for all of the domain-independent
experiments we ran – i.e., excluding the “E” and “F” rows from Table 2,
which used features that were specific to breast cancer. We see that the
results were D-calibrated (i.e., had a HL p-value > 0.05) in all 12
situations, for METABRIC and KIPAN – for all feature groups { A, B, C,
D }, and all 3 learning algorithms { Cox, RCox, MTLR }. We note that
we found that Cox failed this test on other datasets, including BRCA.
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Table 3. D-calibration results from METABRIC, KIPAN, and BRCA, on the held-out test data.
p-values greater than 0.05 suggest the model is good (“D-calibrated”). Note that Cox models fail
D-calibration test for all feature combinations, for BRCA dataset.
ID Feature Groups Algorithms KIPAN METABRIC BRCA
Clinical PCA dLDA HL-Statistic p-value HL-Statistic p-value HL-Statistic p-value
A + − − Cox 7.1455 0.9888 12.6765 0.8104 52.5289 3.1e-05
A + − − RCox 7.1279 0.9890 14.8143 0.6747 4.8816 0.9990
A + − − MTLR 8.2421 0.9748 11.2300 0.8843 6.6300 0.9929
B + + − Cox 5.6697 0.9973 8.1723 0.9760 63.7983 4.9e-07
B + + − RCox 2.5769 0.9973 6.4499 0.9940 6.0013 0.9962
B + + − MTLR 8.4315 0.9714 10.8421 0.9009 8.9895 0.9600
C + − + Cox 10.54166 0.9127 6.0066 0.9962 48.9904 0.0001
C + − + RCox 7.9878 0.9993 4.1344 0.9997 4.6031 0.9993
C + − + MTLR 6.5578 0.9933 8.2000 0.9755 9.2421 0.9539
D + + + Cox 14.1951 0.7162 11.2333 0.8842 25.2241 0.1189
D + + + RCox 8.2420 0.9748 3.4981 0.9999 6.0813 0.9959
D + + + MTLR 7.4947 0.9852 6.5158 0.9936 9.0211 0.9593
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